Mekinist may be available through a mail-order pharmacy. Using this type of service may help lower the drug’s cost and allow you to receive your medication without leaving home.

Study is longest Ph III survival follow-up to date of BRAF V600E/K mutation-positive melanoma patients who received a targeted combination therapy Latest data show an estimated 44% of patients ...

Basel, September 1, 2015 - Novartis today announced that the European Commission has approved the combination of Tafinlar ® (dabrafenib) and Mekinist ® (trametinib) for the treatment of adult ...

Mekinist (trametinib) is newly approved to be used in combination with Tafinlar (dabrafenib). Both drugs were first sanctioned in May 2013 to be used by themselves to battle advanced melanoma ...

Trametinib (Mekinist™) and dabrafenib (Tafinlar™) combination demonstrated overall survival benefit compared to vemurafenib; phase III BRAF V600-mutant metastatic melanoma study stopped early.

Both Tafinlar and Mekinist received initial approval in 2013 as single agents for the treatment of advanced or metastatic melanoma with BRAF V600E mutation. Tafinlar is available as 50mg and 75mg ...

Tafinlar and Mekinist are prescription medications that can be used in combination to treat a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to other parts of the ...

WASHINGTON, Jan. 10 (UPI) -- The U.S. Food and Drug Administration approved Mekinist, or trametinib, in combination with Tafinlar, or dabrafenib, to treat patients with advanced melanoma.

Postsurgical treatment with the combination of the targeted drugs Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in significantly longer relapse-free survival in patients with stage 3 ...

Latest data confirm an estimated 45% of patients who received Tafinlar ® + Mekinist ® combination therapy are alive versus 31% of patients on BRAF monotherapy[1] Second trial to confirm three-year ...

Basel, June 23, 2022— Novartis today announced the US Food and Drug Administration granted accelerated approval for Tafinlar ®+ Mekinist ® for the treatment of adult and pediatric patients 6 ...

Study is longest Ph III survival follow-up to date of BRAF V600E/K mutation-positive melanoma patients who received a targeted combination therapy Latest data show an estimated 44% of patients alive ...